Dosages
Side effects in children
Warnings & precautions in children
Contra-indications in children

Interactions
PK
Renal impairment
References

Paricalcitol

Generic name
Paricalcitol
Brand name
ATC Code
H05BX02

Pharmacokinetics in children

Ages 10-16 Stage 3 CRI Stage 4 CRI
T½ 13.3 ± 4.3 hours 15.2 ± 4.4 hours
Cmax 0.12 ± 0.06 ng/ml 0.14 ± 0.05 ng/ml

Source: SmPC

 

A second drug has not been selected yet.
Press ‘drugs’ followed with and select second drug from list to add the second drug to the comparison.

dose recommendation of formulary compared to licensed use (on-label versus off-label)

No information is present at this moment.

A second drug has not been selected yet.
Press ‘drugs’ followed with and select second drug from list to add the second drug to the comparison.

Available formulations

No information is present at this moment.

A second drug has not been selected yet.
Press ‘drugs’ followed with and select second drug from list to add the second drug to the comparison.

Dosages

Prevention and treatment of secondary hyperparathyroidism in chronic renal disease stage 3-4
  • Oral
    • 10 years up to 17 years
      • Initial dose: 1 microg./dose 3x per week.
      • Maintenance dose: Titrate the starting dose based on the iPTH, serum calcium and serum phosphate levels.  1 - 7 microg./dose 3x per week.
        • Increase in steps of 1 mcg per 4 weeks
        • The dose can be reduced by 1 mcg at any time, or discontinued and resumed later if the patient is already receiving the lowest dose of 1 mcg.
    • ≥ 17 years

      • Initial dose based on the baseline iPTH concentration:
        < 500 pg/ml: 1 mcg/day or 2 mcg 3x per week
        > 500 pg/ml:  2 mcg/day or 4 mcg 3x per week
        Maintenance: titrate based on the iPTH, serum calcium and serum phosphate levels.

        • If the PTH concentration decreases by 30-60%, maintain dosage;
        • if the PTH concentration increases, remains the same or decreases by less than 30%, increase the dose by 1 mcg once a day or 2 mcg 3xd per week, at intervals of 2-4 weeks;
        • if the PTH concentration decreases by more than 60% or if the concentration of intact PTH goes below 60 pg/ml, reduce the dose by 1 µg once a day or 2 µg 3x a week, at intervals of 2-4 weeks; if the patient is already receiving the lowest dose, the dosing frequency can be reduced;

A second drug has not been selected yet.
Press ‘drugs’ followed with and select second drug from list to add the second drug to the comparison.

Renal impaiment in children > 3 months

Not applicable (indicated for children with renal function disorder)

A second drug has not been selected yet.
Press ‘drugs’ followed with and select second drug from list to add the second drug to the comparison.

The complete list of all undesirable drug reactions can be found in the national Summary of Product Characteristics (SmPC) – click here

Side effects in children

Hypercalcaemia, hyperphosphataemia, headaches and nausea have been reported in children.

A second drug has not been selected yet.
Press ‘drugs’ followed with and select second drug from list to add the second drug to the comparison.

The complete list of all contra-indications can be found in the national Summary of Product Characteristics (SmPC) – click here

Contra-indications

No information available on specific contra indications in children.

The complete list of all warnings and precautions can be found in the national Summary of Product Characteristics (SmPC) – click here

Warnings & precautions

No information available on specific warnings and precautions in children.

A second drug has not been selected yet.
Press ‘drugs’ followed with and select second drug from list to add the second drug to the comparison.

Interactions

The complete list of all interactions can be found in the national Summary of Product Characteristics (SmPC) – click here

A second drug has not been selected yet.
Press ‘drugs’ followed with and select second drug from list to add the second drug to the comparison.

Other anti-parathyroid agents
H05BX01

A second drug has not been selected yet.
Press ‘drugs’ followed with and select second drug from list to add the second drug to the comparison.

References

  1. Regiomedica GmbH, SmPC Porontazin (RVG 113731) 26-11-2020 , www.geneesmiddeleninformatiebank.nl
  2. Regiomedica GmbH, SmPC Porontazin (RVG 113731) 26-11-2020, www.geneesmiddeleninformatiebank.nl

A second drug has not been selected yet.
Press ‘drugs’ followed with and select second drug from list to add the second drug to the comparison.

Changes

Changes